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A workflow for the orthogonal identification of 
biotransformation products by HILIC-QTOFMS
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 Determine the degradation rate of emerging contaminants
(pharmaceuticals, illicit drugs) in the aquatic environment under aerobic
conditions
 Study the occurrence and formation of transformation products
 Develop an integrated workflow for suspect and non-target
screening for the identification of biotransformation products
 Study the use of HILIC as a complementary technique for the
identified TPs
 Further investigation for suspect and unknown TPs which may be
eluted better in HILIC conditions
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3Samples of activated sludge from active bioreactors and effluent 
waste water from the WWTP of Athens (Psitalia)
Batch reactors seeded with activated sludge under aerobic  
conditions in room temperature
Spike in a concentration of 2 mg/L
Sampling immediately after spiking and after several time 
intervals (depending on the compound)
Filtration through glass fiber syringe and then through 0.2 μm RC 
filter
LC-HRMS (qTOF) both RP and HILIC
Check for 
sorption to the 
suspended sludge 
particles
Check for abiotic
degradation processes 
(hydrolysis,
volatilization)
Prior to the 
spiking pH and 
TSS, were 
determined.
Biotic 
Reactor
Blank 
Reactor
Sorption 
Reactor
Abiotic
Reactor
•Check for contamination 
between sampling 
•Subtraction of the
background
Aerobic
biodegradation
All reactors were 
covered with 
perforated caps and 
placed on a 
magnetic stirrer to 
aerate the sludge.
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Column: Thermo Acclaim RSLC 
C18, 2.2μm 120 Å, 2.1x100 mm
Mobile Phase & gradient 
program: Bruker Pesticide 
screener
Inj. Volume: 5 μL
Column: Waters BEH Amide 
Acquity 1.7 μm, 2.1×100 mm 
Inj. Volume: 5 μL
Bruker Maxis Impact™ 
Quadrupole-Time-of-Flight
UltiMate 3000™ 
RSLC (Dionex) UHPLC System
RP
HILIC
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Schymanski et al. Environmental Science and Technology (2014) 48(4):2097
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Compilation of suspect list: Metabolite prediction 
tools+ literature
Screening all the time interval chromatograms both in 
RP and HILIC  (+ESI/-ESI)          XIC
Evaluation of candidates (Tentative): meet the set
criteria, absence in the blank, chromatographic
retention time plausibility (time trend)
Acquire MS/MS spectra with inclusion list both in RP 
and HILIC: Interpretation of the fragmentation pathway
Confirmation, if it’s possible with reference standard 
(RT and MS/MS spectra)
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Compilation of the suspect list
•All rules (Phase I & II,
cytochrome P450)
•2 Generations
•Monoisotopic masses (4 digits)
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http://eawag-
bbd.ethz.ch/predict/
Rule based
Microbial catabolic reactions
(reactions found in the 
EAWAG-BBD database/
scientific literature)
EAWAG-BBD 
Pathway 
Prediction 
System
Metabolomic software
Rule based
(Phase I & II 
metabolism, 
cytochrome P450)
Metabolite 
Predict
Compile the suspect list
Save as  .csv file
•Run Bruker Compass Target Analysis 1.3
•Set appropriate thresholds (m/z tolerance and
mSigma)
•Consider mass accuracy and isotopic pattern
to identify plausible TPs
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Screening all the time interval chromatograms both in RP 
and HILIC  (+ESI/-ESI)
Bruker Compass 
Target Analysis 1.3
Identification Criteria
• Mass Accuracy: Error ≤ 
5 ppm
• Distinctive Isotopic fit: ≤ 
100 mSigma
• Intensity > 1000 (+ESI) / 
200 (-ESI)
HILIC
tR=6.30 min
RP
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Evaluation of candidates (Tentative): meet the set criteria,
absence in the blank, chromatographic retention time
plausibility (time trend)
0.00E+00
5.00E+04
1.00E+05
1.50E+05
2.00E+05
2.50E+05
3.00E+05
0 24 48 72 96 120 144
P
e
ak
 a
re
a
Time (hours)
Time Profile of CTR TPs in HILIC
CTR 311 CTR 329 CTR 330 CTR 339A CTR 339B
CTR 341 CTR 343 CTR 344 CTR 355 CTR 357
CTR 359A CTR 359B CTR 360A CTR 360B
0.00E+00
5.00E+03
1.00E+04
1.50E+04
2.00E+04
2.50E+04
0 24 48 72 96 120 144
P
e
ak
 a
re
a
Time (hours)
Time Profile f CTR minor TPs in HILIC
CTR 329 CTR 330 CTR 339B CTR 355 CTR 357
CTR 359A CTR 359B CTR 360A CTR 360B
Until now, Identification level 5: Exact mass of Interest
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Acquire MS/MS spectra with inclusion list both in RP and 
HILIC: Interpretation of the fragmentation pathway CTR 343
Data 
analysis
Smart Formula Manually: C20H24FN2O2
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m/z= 58.0651 
characteristic 
fragment for
N-demethylation
Separation 
of isomers
58.0653
98.0838
130.0554
165.1008
176.0485
191.1183
224.0964
240.2323
+MS2(301.1329), 27.0eV, 6.3min #760
0
20
40
60
80
100
Intens.
[%]
50 75 100 125 150 175 200 225 250 275 300 m/z
58.0653
RAN301
(desmethyl
ranitidine)
Probable 
structure by 
diagnostic 
evidence
98.0848
125.0054
153.0365
176.0487
191.1185
224.0978
+MS2(301.1337), 27.0eV, 6.7min #1491
0
20
40
60
80
100
Intens.
[%]
50 75 100 125 150 175 200 225 250 275 300 m/z
98.0835
130.0549
148.0746
165.1008
176.0478
191.1169
224.0969
+MS2(301.1331), 27.0eV, 3.3min #412
0
20
40
60
80
100
Intens.
[%]
50 75 100 125 150 175 200 225 250 275 300m/z
CTR360B
Probable structure 
by diagnostic 
evidence
14
Carboxylic acid of 
CTR N-oxide
Hydroxylated derivative 
of CTR carboxylic acid
Separation 
of isomers
Isomers
Rt=6.3 min
CTR360A
Tentative candidate
Rt=6.5 min
Rt=6.7 minA
B
CTR360
Probable structure 
by diagnostic 
evidence
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Separation 
of isomers
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Identification level 2b: Probable structure by diagnostic 
evidence
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Identification level 1: Confirmation with Reference 
Standard
Subtraction of the background (Bruker’s MetaboliteDetect 2.0)
Generation of a peak list of unknown
Treat further as “suspect peaks”
Blank Sample
Background 
Subtraction
Sample 
Generation of peak list
Metabolite
Detect
Background Subtraction 
Parameters
Difference
eXpose mode, Ratio: 3
Detect -Mass spectrum 
Parameters
Int. threshold: 30%
Max No. of peaks: 20
Background Subtraction
Sample 
Blank Sample 
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Mass
[M+H]+
Molecular 
Formula
Appearance of 
max peak area
Time 
trend
Id.
Level
Name
Li
d
o
ca
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e
LDC207 207.1504 C12H18N2O 7d ↗↘ 1 MEGX
LDC251 251.1756 C14H22N2O2 2d ↗↘ 1 Lidocaine-N-oxide
LDC219 219.1485 C13H18N2O 1d ↗↘ 2b
LDC233 233.1282 C13H16N2O2 7d ↗→ 4
LDC265 265.1538 C14H20N2O3 9d ↗→ 4
C
it
a
lo
p
ra
m
CTR311 311.1554 C19H19FN2O 6 d ↗ 1 Desmethyl CTR
CTR329 329.1660 C19H21FN2O2 6 d ↗ 2b Desmethyl CTR amide
CTR330 330.1500 C19H20FNO3 6 d ↗ 2b Desmethyl CTR carboxylic acid
CTR339A 339.1503 C20H19FN2O2 6 d ↗ 1 3-Oxo-CTR
CTR339B 339.1880 C21H23FN2O 6 d ↗ 2b Methylated derivative of CTR
CTR341 341.1660 C20H21FN2O2 3 d ↗↘ 2a CTR-N-oxide
CTR343 343.1816 C20H23FN2O2 6 d ↗ 1 CTR amide
CTR344 344.1656 C20H22FNO3 5 d ↗ 1 CTR carboxylic acid
CTR355 355.1457 C20H19FN2O3 6 d ↗ 3 Hydroxylated derivative of 3-Oxo-CTR
CTR357 357.1609 C20H21FN2O3 6 d ↗ 2b Amide of 3-Oxo-CTR
CTR359A
359.1765 C20H23FN2O3
6 d ↗ 3 Hydroxylated derivative of CTR amide
CTR359B 4 d ↗↘ 2b Amide of CTR-N-oxide
CTR360A
360.1606 C20H22FNO4 6 d
↗ 3 Hydroxylated derivative of  CTR carb.acid
CTR360B ↗ 2b Carboxylic acid of CTR-N-oxide
M
tf
MTF103 103.0614 C2H6N4O 2d ↗ 1 Guanylurea
PC TP
Mass 
[M+H]+
Molecular 
Formula
Appearance of 
max peak area
Time 
trend
Id.
Level
Name
R
a
n
it
id
in
e
RAN286A
286.0856 C11H15N3O4S
1d ↗↘ 4 -
RAN286B
2d ↗→ 4 -
RAN286C
10h ↗↘ 4 -
RAN301A
301.1329 C12H20N4O3S 10h ↗↘
2b
desmethyl RAN
2bRAN301B
RAN302A
302.0805 C11H15N3O5S
1d ↗ 3
RAN302B 1d ↗↘ 3
RAN316A
(2peaks) 316.1331
3d ↗ 3
RAN316B 3d ↗ 3
RAN317 
(2peaks)
317.1278 C12H20N4O4S 3d ↗ 3 Desmethyl RAN-S-oxide
RAN331A 
(2peaks) 331.1435 C13H22N4O4S
1d ↗↘ 1 RAN-S-oxide
RAN331B 1d ↗↘ 1 RAN-N-oxide
A
to
rv
a
st
a
ti
n ATR515 515.2341 C31H31FN2O4 2d ↗ 2b β-oxidation product of ATR
ATR471 471.2078 C29H27FN2O3 2d ↗ 2b β-oxidation product of ATR515
ATR487A
487.2028 C29H27FN2O4
2d ↗ 3
Monohydroxylation of ATR471
ATR487B 2d ↗ 3
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5 pharmaceuticals (metformin, ranitidine, lidocaine, citalopram and
atorvastatine) were investigated for their TPs under aerobic
biodegradation experiments and 34 TPs were identified, in total.
Nine of them were confirmed by a reference standard and the
majority of the rest reached Id. Level 2: probable structure by
diagnostic evidence.
HILIC was presented to be fit for the orthogonal identification of TPs
and suitable for screening of more polar metabolites
HILIC provided better peak shapes and greater intensities in some of
the identified TPs.
HILIC also, permitted the identification and characterisation of
isomeric TPs, due to the better detection sensitivity that provided
clearer spectra for interpretation.
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